PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium
December 05, 2023 07:00 ET
|
PreludeDx
In data presented at SABCS23, DCISionRT changed radiation therapy decisions in 41% of DCIS patients
UPDATE - PreludeDx Presents Risk Assessments for DCIS Patients Using Clinicopathologic-Based Models Like RTOG 9804 and MSKCC Compared to DCISionRT®
October 02, 2023 10:17 ET
|
PreludeDx
LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study...
Atossa Genetics Signs Distribution Agreement With McKesson Medical-Surgical
September 18, 2013 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Sep 18, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that it has entered into a nationwide distribution agreement with...
Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the Breast Cancer Symposium 2013
September 06, 2013 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Sep 6, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, will display its ForeCYTE Breast Health Test at the 7th annual Breast Cancer...
Atossa Genetics Reports Second Quarter 2013 Results and Operating Highlights
August 14, 2013 16:01 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Aug 14, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company™, today announced its second quarter 2013 financial results and corporate...
Atossa Genetics to Announce Second Quarter 2013 Results on Wednesday, August 14, 2013
August 06, 2013 16:01 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Aug 6, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, today announced that it will issue financial results and corporate highlights for...
New ASCO Clinical Practice Guideline for Breast Cancer Risk Reduction May Be Insufficient for Widespread Reduction, Atossa Genetics Says
August 05, 2013 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Aug 5, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, said that the new ASCO clinical practice guideline for the use of pharmacologic...
Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the 2013 ASCO Annual Meeting
May 23, 2013 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 23, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, will display its ForeCYTE Breast Health Test at the 2013 American Society of...
Atossa Genetics: New Recommendations for Preventive Drug Treatment for Breast Cancer Are Helpful but Incomplete
April 23, 2013 10:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Apr 23, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, believes that new recommendations published on April 16 by the U.S. Preventative...
Atossa Genetics to Present at FSX San Francisco Investor Conference
April 23, 2013 08:00 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Apr 23, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Kyle Guse, CFO and General Counsel, will present the...